Journal profile · Pathology
Experimental and Molecular Pathology
ISSN 0014-4800 · eISSN 1096-0945 · Academic Press Inc. · UNITED STATES · Bimonthly · Founded 1962
Experimental and Molecular Pathology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4.08; fully open access; APC about USD 2,640; median 137 days to acceptance (93 articles, last 24 months); 65 articles in 2025; indexed in SCIE and Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Experimental and Molecular Pathology is published by Academic Press Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Human auditory perception and evaluation and Educational Robotics and Engineering, together about 21.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Experimental and Molecular Pathology is an open access, peer-reviewed journal presenting original research and review articles across different fields of life science and medicine.We welcome research addressing questions related to human pathology, with a particular emphasis on the preclinical aspects, in: biology (cellular, molecular, micro), biochemistry, genetics (epi), genomics, virology, immunology, oncology, and regenerative medicine.Manuscripts heavily relaying on computational biology are acceptable ONLY if the data is at least partially confirmed by cell-biology lab experiments.Review manuscripts may be accepted if of sufficient quality and if the corresponding author(s) have sufficient expertise confirmed by authorships on subject-relevant research papers. Meta-analysis manuscripts may be considered on a case-by-case basis, subject to editorial assessment of their novelty, methodological rigor, and relevance to the journal.Our mission is to advance scientific knowledge by publishing manuscripts with macro and micro perspectives and techniques, during health, disease, and disorder processes.We support rigorous science, performed with high ethical and publishing standards; any paper that improves the scientific state of knowledge will be considered for publication.Publishing with us will enable your research to be freely accessible to the wider community.
From the journal's Aims & Scope
Research area (LetPub): Pathology
Editor-in-chief Marek ŁosPublisher website
Editorial board by country: 7 in mainland China (about 12%); most named United States 21, Sweden 8, Mainland China 7, Spain 4, Germany 3 (60 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance8%
- Human auditory perception and evaluationEngineering7.8%
- Educational Robotics and EngineeringComputer Science5.8%
- Liver Disease Diagnosis and TreatmentMedicine5.3%
- Cell Adhesion Molecules ResearchMedicine5.1%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.8%
- Drug-Induced Hepatotoxicity and ProtectionPharmacology, Toxicology and Pharmaceutics4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
Early warning / risk: CAS Early Warning Journal List: listed in the 2021 edition (high risk) and the 2020 edition (medium risk); not listed in the other 4 editions.LetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.08LetPub ·
- Impact factor (publisher)
- 4.1Publisher website ·
- CiteScore 2026-06
- 6.3LetPub ·
- CiteScore (publisher)
- 6.3Publisher website ·
- SJR 2026-06
- 1.11LetPub ·
- SNIP 2026-06
- 0.97LetPub ·
- h-index
- 60LetPub ·
- h-index
- 113OpenAlex ·
- i10-index
- 3,081OpenAlex ·
- 2-year mean citedness
- 3.82OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 54LetPub ·
Articles by year OpenAlex count · 5,066 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 57 | 57 | 16 |
| 2025 | 65 | 65 | 270 |
| 2024 | 55 | 55 | 390 |
| 2023 | 23 | 23 | 253 |
| 2022 | 78 | 22 | 720 |
| 2021 | 97 | 20 | 1,170 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
137 daysMedian, submission to acceptance · P25–P75 103 days – 172 days
- Acceptance to online
- median 7 days (93 articles)
- Submission to online
- median 144 days
- Sample
- 93 articles with submission and acceptance dates (140 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4.5 monthsLetPub ·
- Average acceptance (community reports)
- 62.5%LetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 56 daysPublisher website ·
- Submission to acceptance
- 141 daysPublisher website ·
- Acceptance to publication
- 7 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,640 / EUR 2,470 / GBP 2,110 / JPY 327,440 | — | — | |
| Publisher website | USD 3,190 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare1 items from the author guidelines
- Abstract
- ≤ 250 words
Article types accepted3
- original researchExperimental and Molecular Pathology presents original research and review articles on the biology of all organisms, during health and disease processes. The jo…Length not stated
- review articleExperimental and Molecular Pathology presents original research and review articles on the biology of all organisms, during health and disease processes. The jo…Length not stated
- review articlesExperimental and Molecular Pathology presents original research and review articles on the biology of all organisms, during health and disease processes.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Publishing ethics Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Academic Press Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1962
- ISSN
- 0014-4800
- Electronic ISSN
- 1096-0945
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Experimental and Molecular Pathology
What CAS zone is Experimental and Molecular Pathology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Experimental and Molecular Pathology is in Zone 4 of Medicine, and in Zone 3 of the minor category Pathology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Experimental and Molecular Pathology?
The latest impact factor listed by LetPub is 4.08; CiteScore 6.3, h-index 113.
How long does peer review take at Experimental and Molecular Pathology?
Based on the dates recorded on 93 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 137 days (interquartile range 103–172 days); authors report an average review time of about 4.5 months. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Experimental and Molecular Pathology based?
Of the 60 board members whose country the journal's board page names, 7 (about 12%) are in mainland China; the countries named most often are United States (21), Sweden (8) and Mainland China (7). Counted from the institutions listed on the board page; for reference only.
Which databases index Experimental and Molecular Pathology?
According to LetPub and DOAJ records, Experimental and Molecular Pathology is indexed in SCIE, Scopus and DOAJ.
Is Experimental and Molecular Pathology open access, and what is the APC?
Experimental and Molecular Pathology is a fully open-access journal. APC about USD 2,640.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .